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ABSTRACT
Background:
State-of-the art selection methods fail to identify weak but cumulative effects of features found
in many high-dimensional omics datasets. Nevertheless, these features play an important role in
certain diseases.
Results:
We present Netboost, a three-step dimension reduction technique. First, a boosting-based filter
is combined with the topological overlap measure to identify the essential edges of the network.
Second, sparse hierarchical clustering is applied on the selected edges to identify modules and
finally module information is aggregated by the first principal components. The primary analysis is
than carried out on these summary measures instead of the original data.
We demonstrate the application of the newly developed Netboost in combination with CoxBoost for
survival prediction of DNA methylation and gene expression data from 180 acute myeloid leukemia
(AML) patients and show, based on cross-validated prediction error curve estimates, its prediction
superiority over variable selection on the full dataset as well as over an alternative clustering
approach. The identified signature related to chromatin modifying enzymes was replicated in an
independent dataset of AML patients in the phase II AMLSG 12-09 study.
In a second application we combine Netboost with Random Forest classification and improve the
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disease classification error in RNA-sequencing data of Huntington’s disease mice.
Conclusion:
Netboost improves definition of predictive variables for survival analysis and classification. It is
a freely available Bioconductor R package for dimension reduction and hypothesis generation in
high-dimensional omics applications.
Background
Microarray, sequencing and other high-throughput functional genomics technologies are developing rapidly, incorpo-
rating more and more features. A major challenge in biomedical research is the contrast of these high-dimensional
datasets and the related investigation of potentially hundreds of thousands of features with only a limited sample pop-
ulation in the range of tens to a few hundreds. This gives rise to dimension reduction techniques with the aim of identi-
fying the subspace with minimal dimensions and the best characterization of the outcome variable simultaneously[1].
Many times, methods which were originally developed for the selection of tens of clinical variables are now faced
with the challenge of selecting from hundreds of thousands or even from millions of variables. In cases where it is not
expected that a singular feature dominates the effect but rather that a larger group of features works cumulatively, the
challenge becomes even greater.
In acute myeloid leukemia (AML) part of the epigenotype of the disease is a global increase in DNA methylation
in regulatory regions [2]. Furthermore, for elderly patients the only effective drugs that counteract this effect are
hypomethylating agents [3, 4, 5]. From this it is known that the state of methylation fulfills an important role in
this disease. Nevertheless it has been difficult to incorporate DNA methylation markers in patient relevant statistics
like survival prediction [3, 6]. Predictive methylation sites in AML patients treated with chemotherapeutics [7] and
predictive sites from chronic myelomonocytic leukemia patients treated with hypomethylating drugs [8] could not be
replicated for AML patients treated with hypomethylating drugs.
Weighted Gene Co-expression Network Analysis (WGCNA) [9] is a versatile framework to extract networks from
high-dimensional data. It is able to identify biologically functional subgroups, called modules, under many differing
settings [10, 11, 12]. When relating this structured information to the outcome of interest, additional challenges are
faced. We are interested in the subgroups of features which are most central to the function of the modules. The
method has to be even more selective in differentiating background noise from true connections to be used to explain
the interplay of differing molecular levels, like gene expression and DNA methylation.
With Netboost, we propose a procedure to reduce dimensions within high-dimensional datasets. We put a specific
emphasis on large subgroups of features that show a shared effect. For this we aggregate subgroup information before
applying the primary analysis strategy. In public domain examples we show that we are able to extract patient relevant
information from multiple high-dimensional measurement types.
The paper is organized as follows. Section Methods outlines the newly developed Netboost and describes the imple-
mentation. In Section Results Netboost is applied in two public domain datasets and its performance is compared
with two other approaches for each application. Section Discussion outlines the limitations and the potential future
direction of the proposed method to conclude the paper.
Methods
Netboost is a three-step procedure. As shown in Figure 1, in the first step we calculate the boosting-based filter
and a sparse distance matrix between features (Section Boosting-based filter and Distance calculation). From this
combination we can reduce the network to its essential edges and remove spurious connections, originating from noise.
We still retain the interconnectedness and stability of complex network structures including indirect connections that
occur in many omics datasets reflecting biological pathway structures.
The second step consists of sparse hierarchical clustering and the dynamic tree cut procedure to determine modules
from the dendrogram (Section Hierarchical clustering and decomposition into modules) to transfer the network into a
clustering.
Subsequently in step three, we aggregate the information in the modules by their first principal components (PCs)
(Section Aggregation of module information) to achieve a low-dimensional representation of the original data.
In this network-based dimension reduction method we modify the WGCNA by the addition of a multivariate filter
and by the application of sparse hierarchical clustering. Netboost is then followed by the primary analysis approach
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with the aggregated module information instead of with the original omics data. Here we present two applications,
CoxBoost [13] to fit a Cox proportional hazards model integrated with a variable selection (Section TCGA AML:
Methylation and gene expression predictive of overall survival) and a classification analysis by Random Forests [14]
(Section Huntington’s disease: Gene expression and CAG repeats).
Module detection
Let X be a n × p-dimensional data-matrix, where n  p with n being the number of samples and p the number of
features. We assume X to be continuous in each feature.
Boosting-based filter
To first identify a general structure of our network we aggregate a filter of important network edges by boosting. Let
m ∈ N index samples, i, j ∈ N index variables and
Xi := Xm≤n,i and X−i := Xm≤n,j 6=i.
We fit
Xi = X−iβj≤p−1,
with β ∈ R(p−1). Here, we perform component-wise likelihood-based boosting to fit a linear approximation of the
outcome variable. In each iteration we fit the linear base learners using Fisher scoring with respect to the overall
likelihood function one-by-one while keeping all other base learners fixed [15, 16]. Boosting is stopped after a given
fixed number of steps. For all βj 6= 0 we then add the tuple (i, j) to the filter. We estimate an undirected network,
therefore the order of (i, j) is irrelevant. We define the filter by
F := {(i, j), (j, i)|∃i, j ∈ N βi 6= 0 in Xj = X−jβ}.
By pruning the network to F we remove uninformative edges, reduce computational load and noise in subsequent
steps.
Distance calculation
For tuples in F we define the adjacency of two features analogous to [9] by the power adjacency function. For all
other tuples the adjacency is set to 0. Hence, we have
aij :=
{|cor(Xi, Xj)|b if (i, j) ∈ F ,
0 else,
where b is chosen data-based by the scale free topology criterion [17] on a random subset of features. cor denotes the
Pearson correlation.
We combine the topological overlap measure (TOM) [18] with F and define
TOMij :=

1 if i = j,∑
u 6=i,j aiuauj+aij
min(
∑
u 6=i aiu,
∑
u6=j auj)+1−aij if (i, j) ∈ F ,
0 else.
(1)
As aij ∈ [0, 1] it follows that TOMij ∈ [0, 1]. These similarities are inverted to distances by
DistTOMij := 1− TOMij . (2)
Hierarchical clustering and decomposition into modules
We apply the unweighted pair group method with arithmetic mean (UPGMA) [19] to DistTOM. Parts of the network
where no path exists in F are clustered independently. A path between Xi and Xj exists exactly then when there is
an l ∈ N such that there are t1...l ∈ F with i = t11, j = tl2 and ∀s : 1 ≤ s ≤ l − 1 ts2 = t(s+1)1. The dendrograms
resulting from these hierarchical clusterings are separated into modules by the Dynamic Tree Cut procedure [20].
Thus, features which are topologically close on the filtered edges are grouped into modules.
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Aggregation of module information
By design the first PC explains the variation in one dimensional space as much as possible. Therefore, we aggregate
the information in each module by its first PC, the so called eigengenes [9]. In a final step modules with highly
correlated first principal components are merged to further reduce dimensionality. We define Eq as the first principal
component of the qth module and
Xmodules := (E
T
1 , . . . , E
T
m),
where m is the number of detected modules. Xmodules has the dimension n ×m where m  p. Due to its definition
a substantial part of variation in X is conserved in Xmodules. At the same time the dimensionality is considerably
reduced.
Module selection and evaluation
Variable selection is performed analog to the primary analysis approach, but it is done on the set of eigengenes rather
than on the set of features.
CoxBoost
We apply CoxBoost [13] to integrate the potentially still high-dimensionalXmodules with clinical covariates and survival
data as the primary outcome by likelihood-based boosting. Analysis is implemented with the CoxBoost R package
[21]. The stopping criterion is chosen by cross-validation and a Cox proportional hazards model is fitted.
Prediction errors
To evaluate the performance of CoxBoost models we used the peperr R package [22] which implements .632+ predic-
tion errors based on subsamples without replacement as recommended in [23]. In high-dimensional data constellations
bootstrap samples with replacement often lead to overly complex models. Therefore, subsamples without replacement
of 63.2% of the samples, which is equal to the expected number of unique observations in one bootstrap sample drawn
with replacement, are implemented. Variability of prediction error curves is displayed by the distribution of integrated
prediction error curves of the subsamples.
Random forests
We apply random forests as described in [14] to classify samples based on Xmodules to their disease severity classes.
To adequately explore the space of possible trees, also for the most high-dimensional of the analyses, we grow 10,000
trees in each analysis.
Implementation
Netboost is built as an R package. It has been tested under Linux and macOS. A Windows implementation is currently
not planned due to compiler dependencies.
As depicted in algorithm 1 we first calculateF . Under the assumption of continuousXj and after scaling and centering
each we efficiently implement the likelihood based boosting. The subsequent calculation of the adjacencies and the
TOM are performed exclusively on network edges inF . Then the sparse distance matrix is exported to Sparse UPGMA
by [24]. Here all empty edges where the nodes are connected indirectly are assumed to have the maximal distance in
the network and completely unconnected nodes of the network are processed separately in independent clusterings.
This agrees with the described method as all connected nodes not in F have the distance of 1. By applying the filter we
therefore reduce the memory load and computational burden massively as the filter is smaller than the whole network
by orders of magnitudes as demonstrated in the examples in section Results.
The algorithm is freely available as a Bioconductor R package at http://bioconductor.org/packages/release/bioc/html/netboost.html.
All functionality of Netboost is available from within R whereas substantial parts of the algorithm are implemented in
C++. Sparse UPGMA is part of the standalone MC-UPGMA software (for details see [24]). It is distributed with the
Netboost R package. For extraction of modules we applied the WGCNA [9] and dynamicTreeCut [20] R packages.
As an example for the computational demand Netboost was run on a dataset with 180 samples and 413,169 features
(for details see section TCGA AML: Methylation and gene expression predictive of overall survival). Applying two
Xeon E5 2690v3 at 2.6GHz (2x12cores) and 40 GB of RAM it took Netboost 13.94 hours to compute.
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Algorithm 1: Netboost
Input: X , steps, minModuleSize, MEDissThres
Result: Xmodules
F = ∅;
for j ← 1 to p do
fit Xj = X−jβ;
F = F ∪ {(i, j)|∃i ∈ N βi 6= 0};
end
F = {(i, j)|(i, j) ∈ F ∨ (j, i) ∈ F};
randomFeatures = X[,sample(n= min(10,000,ncol(X))];
scaleFreeTopologyCriterium(randomFeatures)→ b;
for (i, j) ∈ F do
aij = |cor(Xi, Xj)|b;
end
for (i, j) ∈ F do
compute DistTOMij := equation (2);
end
sparseUPGMA(DistTOM)→ dendrogram;
cutreeDynamic(dendrogram, minModuleSize)→ modules;
for q ∈ modules do
compute first principal component Eq;
end
while ∃q, q′ with cor(Eq, Eq′ ) > (1−MEDissThres) do
merge(q, q′);
compute first principal component of merged module;
end
Results
We apply Netboost to two datasets. In section TCGA AML: Methylation and gene expression predictive of overall
survival it is applied to DNA methylation and gene expression data from The Cancer Genome Atlas (TCGA) AML
cohort to predict survival (see CoxBoost). In section Huntington’s disease: Gene expression and CAG repeats it is
applied to RNA sequencing data to classify (see Random forests) Huntington’s disease severity in mice.
TCGA AML: Methylation and gene expression predictive of overall survival
We selected the 180 AML patients in the public domain TCGA database for which overall survival data, methylome
and gene expression measurements were available. TCGA data was already preprocessed and normalized. Methylation
was quantified with Illumina Infinium HumanMethylation450 BeadChip arrays and gene expression by Affymetrix HG
U133 Plus 2.0 arrays. Thereby 396,065 methylation and 17,104 gene expression measurements were incorporated.
We compared the following three schemes each with and without a clinical score. The clinical score is a dichotomized
version of the linear predictor of a Cox proportional hazards regression model [25] of age at diagnosis and cytogenetic
risk group, assessed as low, intermediate or high. Baseline hazards were estimated in separate strata according to sex.
The score was solely used to evaluate Netboosts performance.
In the models with the clinical score it was set as mandatory and thereby unpenalized in CoxBoost. Thereby, DNA
methylation and gene expression information was only added in these models if they could improve the prediction on
top of the clinical score.
1. Direct application: Application of CoxBoost on the full dataset X .
2. Blockwise modules: The same approach as in Netboost but with the module detection done by blockwise
WGCNA.
3. Netboost: Module PCs are calculated as described in section Methods. CoxBoost is applied to these.
The blockwise modules approach was the initial inspiration for the Netboost method. They coincide with one another
apart from Netboosts added boosting-based filter and that X has to be separated into feature subsets for WGCNA
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so that the whole correlation matrix on the individual subsets can be computed. This is accomplished with k-means
clustering and later aggregation via correlated eigengenes [9].
CoxBoost was implemented in all analyses in R with the peperr package [22]. We used 10-fold cross validation to
estimate the optimal stopping criterion on the interval from 0 to 100. We applied 200 resampling steps to estimate the
632+ prediction errors.
In models 1.-3. we integrated the analysis without the clinical score. The direct application on the full dataset, X ,
selected two features and the 632+ prediction error curve, depicted in Figure 2, shows no improvement over the
null model. The estimated .632+ prediction errors for days since diagnosis are given in blue for the null model and
dashed blue for the clinical model. Prediction error curves based solely on DNA methylation and gene expression
are presented in black: The solid line for the direct application of CoxBoost, the dotted line for the combination with
weighted gene co-expression network analysis (WGCNA) and the dashed line for the combination with Netboost. The
corresponding prediction error curves additionally based on unpenalized clinical data are presented in red.
Blockwise modules identified 568 modules with a mean module size of 671 in the range of 10 to 57,548. Ten was set
as the minimum module size. Henceforth, 92% of the features were assigned to modules. The proportion of variance
explained by eigengenes ranged from 23.9% to 94.6% (median = 50.5%). In the WGCNA aggregated XWGCNA modules
two modules were selected by CoxBoost summarizing 26 features.
For Netboost the multivariate filter was stopped after 20 steps and resulted in a filter of 4,956,518 network edges. This
represents approximately 0.003% of the edges. Based on this Netboost identified 739 modules with an average module
size of 52 in the range of 10 to 4,251. Accordingly 9% of the features were assigned to modules. The dendrogram
based on the sparse network is depicted in Figure 3. Netboost eigengenes generally explained a higher proportion of
variance (median = 66.5%, range = [45.7%, 97.3%]). CoxBoost selected six modules from the Netboost aggregated
XNetboost modules, summarizing 278 features. None of the features are shared by the selected Netboost modules and the
selected WGCNA modules.
As shown in Figure 2 the higher complexity indeed corresponds to a better prediction performance in the 632+ predic-
tion errors. The blockwise modules approach was able to extract some information but was outperformed by Netboost.
This also holds true when incorporating the variability of the individual 632+ resampling steps in Figure 4.
As depicted in Figure 2 and Figure 4, once we added the clinical score as a mandatory covariate, none of the three
approaches was able to extract substantial additional information from the molecular data. Overall, when comparing
integrated prediction errors all analyses but the direct application of CoxBoost showed significant improvements over
the null model (one-samples Student’s t-test, p-value< 0.05). Netboost including the clinical score had the lowest p-
value (p-value = 1.3e-27). When comparing analyses with each other the integration with WGCNA and the Netboost
significantly improved CoxBoost (p-value = 0.0437 and p-value = 0.0002, respectively) and Netboost improved the
accuracy of survival prediction on top of WGCNA (p-value = 0.0413). Furthermore, all analyses including the clinical
score significantly improved prediction when compared with any analysis without the clinical score. In between
analyses including the clinical score no significant differences were observed (two-samples Student’s t-test, p-value<
0.05).
To investigate the possibility of the molecular information extracted by Netboost being a surrogate for the clinical
score, we fitted logistic regression models for the module eigengenes to the clinical score. We compared random
selections of features out of all DNA methylation and gene expression features and modules, WGCNA and Netboost
respectively, of similar size to the modules selected by WGCNA and Netboost and the modules selected for survival
prediction. We fitted 500 models on subsamples of size 100 and evaluated the misclassification-rate on the remaining
samples. For the random selections, features were reselected with each fit. As shown in Figure 5, the selected Netboost
modules approximated the clinical score best.
To further comprehend the differences in the clustering we took random subsets of size 100 and compared the resulting
Netboost and WGCNA clusterings using pairwise adjusted Rand Indices and Jaccard Indices [26, 27]. Additionally,
we calculated kmeans clusterings with the number of clusters fixed to the median number of clusters in Netboost
clusterings (646) and WGCNA clusterings (533) and generated random clusterings with the respective number of
clusters. The Rand Index is defined as the proportion of consistently clustered features between the two clusterings
so tuples of features that are in both clusterings either in a common cluster or in both clusterings in differing clusters.
The adjusted Rand Index corrects this for the expected number of consistent tuples given that the number of features
and the number of clusters such that E[adjusted Rand Index] = 0. The Jaccard Index is similar to the Rand Index,
however it disregards tuples for features that are in different clusters for both clusterings. Both indices are less than or
equal 1 and exactly 1 for identical clusterings. As seen in Figure 6 both random clusterings had consistently pairwise
indices of 0 and both kmeans clusterings were outperformed by WGCNA and Netboost with respect to both metrics.
With respect to the adjusted Rand Index Netboosts median was below WGCNAs median while the order of minima
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was vice versa. When comparing the Jaccard Indices, Netboost outperforms WGCNA and shows a higher similarity
for all pairwise comparisons with respect to this measure.
Netboost modules reflected known biology. 206 of the 739 Netboost modules consist of CpGs within 1,000 base
pairs demonstrating the strength of local dependency in DNA methylation data. Netboost re-identified data-driven the
association of CpGs in close proximity and cis association of gene methylation and expression. In total, six different
modules were selected that were variable in size and composition: 4 of the 6 modules consisted only of CpGs, one
predominantly of CpGs and, in addition, 2 RNAs, one module only of 14 RNAs. The total number of CpGs varied
from 10 to 88. The largest module (88 CpGs) contained numerous genes associated with hematopoiesis, such as WT1
and CXCL2. The 2nd largest module (80 CpGs, 2 RNAs) represented several genes encoding chromatin-modifying
enzymes such as the H3K9 histone methyltransferase EHMT1 and the DNA demethylase TET3. To illustrate the
strong association of this chromatin associated module alone we plotted stratified Kaplan-Meier curves according to
its bimodal distribution (Figure 7 A,B). The p-value of the likelihood ratio test of the dichotomised module levels (p-
value = 7.0e-7) surpassed the one of the continues module levels (p-value = 4.0e-6); indicating that there might indeed
be two states of these genes. Several of these have already been implicated in AML pathogenesis and appear very
promising for future predictive scores. Specifically, 4 CpGs mapped to the gene encoding EHMT1, also represented
in the 4-gene methylation signature described by [7].
To validate the Netboost signature, we transferred it to DNA methylation data generated on pre-treatment patient
samples from the phase II AMLSG 12-09 study [28]. In this study, DNA methylation based on the same Illu-
mina Infinium 450k array and overall survival was available for 55 AML patients. For processing and quality
control of the raw methylation data, a customized version of the CPACOR pipeline [29] was used for data nor-
malization and calculation of beta values. The complete preprocessing pipeline is available on Github (https:
//github.com/genepi-freiburg/Infinium-preprocessing). As no data on gene expression was available
one of the six modules could not be studied at all, while 2 were partially available (79 of 82 and 64 of 67 features) and
3 modules were available with all features. While the cox proportional hazards model of these five modules was not
significant in this smaller dataset (p-value = 0.4) the above mentioned chromatin associated module alone did replicate
(p-value = 0.04). Furthermore, this module exhibited a similar bimodal pattern as in TCGA and again, dichotomization
led to a smaller p-value (p-value = 0.01, Figure 7 C,D).
After the detailed analysis of the TCGA-AML DNA methylation and gene expression dataset we downloaded three
more TCGA datasets; DNA methylation data of 774 breast invasive carcinoma (TCGA-BRCA) and 315 kidney renal
clear cell carcinoma (TCGA-KIRC) patients and miRNA data of 464 ovarian serous cystadenocarcinoma (TCGA-OV)
patients with available overall survival information. The 1,422 TCGA-OV miRNAs without missings and the 20,000
CpG sites with the largest variance for TCGA-BRCA and TCGA-KIRC respectively were selected for analysis. For
each dataset we performed the same three analyses as for AML and calculated the 632+ prediction error estimates.
Boxplots of the integrated prediction errors on the test set of the individual subsamplings are depicted in Figure 8.
For clear cell carcinoma we observed similar performance as in AML. The integration with WGCNA significantly
improved CoxBoost (p-value = 0.0013) and integration with Netboost improved the accuracy of survival prediction
on top of WGCNA (p-value = 0.0006). For the other two datasets none of the three approaches was able to improve
overall survival prediction.
Huntington’s disease: Gene expression and CAG repeats
Huntington’s Disease (HD) is driven by the number of CAG repeats in the huntingtin gene. In [12] WGCNA revealed
13 striatal gene expression modules that correlated with CAG length and age in a HD knock-in mouse model. Further it
was shown that several of these effects translate to other HD models and patients. Recently, the analysis was extended
to miRNA from the same mice in [30].
To evaluate the performance of Netboost we used the mRNA dataset in an inverse setup and determined the prediction
errors in a classification task. We selected the 48 mRNA-sequencing samples from mouse striatum consisting of
six genetically engineered disease severities (20, 80, 92, 111, 140 and 175 CAG repeats) with four female and four
male mice all harvested at 6 months. We downloaded the preprocessed mRNA-sequences from the Gene Expression
Omnibus. After removal of invariant transcripts, data consisted of 28,010 transcripts.
We compared three setups:
1. Direct application: Random forest (RF) on the full dataset X .
2. Blockwise modules: Blockwise WGCNA + RF on module PCs
3. Netboost: RF on module PCs determined by Netboost
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RF was implemented in all analyses in R with the randomForest package [14]. We used 200 iterations of leave-one-out
cross-validation.
The direct application on the full dataset, X , resulted in a mean prediction error of 30.8%.
Blockwise modules identified 61 modules with a mean module size of 423 in the range of 11 to 6221. Ten was set
as the minimum module size. Henceforth, 92% of the features were assigned to modules. In the HD application the
proportion of variance explained by eigengenes was lower than in the AML data (median = 42.1%, range = [29.3%,
63.4%]). On the WGCNA aggregated XWGCNA modules the mean prediction error was 37.1%.
For Netboost the multivariate filter was stopped after 20 steps, resulting in a filter of 247,497 network edges. This
represents approximately 0.06% of the edges. Based on this Netboost identified 106 modules with an average module
size of 46 in the range of 10 to 561. Accordingly 17% of the features were assigned to modules. Eigengenes of
the Netboost modules explained a higher proportion of variance (median = 66.2%, range = [52.3%, 84.9%]). On
the Netboost aggregated XNetboost modules the mean prediction error was 28.2%. The dendrogram based on the sparse
network is depicted in Figure 9. As shown for 25, 20 and 15 steps the clustering is stable under the choice of boosting
steps.
Two-sample tests for equality of proportions with continuity correction showed significant differences in means of
prediction errors with Netboost errors being smaller than direct application (p-value = 0.019) and WGCNA (p-value
< 2.2e-16) and direct application errors being smaller than WGCNA (p-value < 2.2e-16).
Discussion
Netboost is designed in an unsupervised manner. While a supervised approach to module detection would possibly
further improve accuracy, these approaches are complementary.
In [31] another approach for data with correlated features is proposed. The first step is to cluster the features, and then
choose a cluster representative based on prediction performance. The second step is to apply either lasso or marginal
significance testing on these representatives. Apart from differences in the applied clustering technique as with other
supervised clustering techniques this might lead to improved predictive performance but hinder the interpretation of
the selected clusters. Here, the primary aim is to maximize predictive power and thereby optimize the algorithm for
biomarker detection. This is done at the cost of potentially introducing some form of bias. Dependent on size and
connectivity of the module the supervised selection might pick up peripheral features - voiding their function as a
representative.
Thereby, we are hindered if we are interested in the biological interpretation of identified biomarkers in context of
the network. Keeping outcome and network detection separate allows for unbiased interpretation of any potential
connections between subsequently in the primary analysis selected modules and the outcome.
In [32] two extension to sparse canonical correlation analysis (CCA) [33] are introduced. First they propose a su-
pervised form of sparse CCA and secondly they generalize the framework from two to multiple datasets. With this
they offer a framework for identification of sparse linear combinations of the multiple sets of variables that are highly
correlated with each other and associated with the outcome. While Netboost can also identify cross-omics corre-
lations associated with the outcome, [32] omit within datatype connections and optimize their algorithm solely for
cross-dataset combinations.
Starting with the WGCNA methodology our original design is the introduction of the filtering step before constructing
the correlation-based network. Here, we chose a boosting based edge detection to allow for efficient selection of essen-
tial edges. By introduction of this sparsity to the network we modified the TOM based distance and replaced UPGMA
with the sparse UPGMA by Loewenstein et al [24]. As Netboost is still based on the Pearson correlation coefficient
and PCA based dimension reduction Netboost and WGCNA share many of the same advantages and drawbacks due
to their similarity in design.
Having a single representative for each cluster might be an advantage for biomarker identification. Another approach
to consider for this purpose are hub genes replacing the eigengenes we applied, as discussed in [34] and [35]. A
hub gene is the most central node with the highest connectivity of the module as opposed to a summary measure
and therefore allows cost efficient replication and application as a biomarker [36]. Eigengenes might be superior in
mechanistic studies, exploratory studies and the identification of previously unknown biological features.
In general for dimension reduction of modules, eigengenes optimize explained variance with respect to the predefined
dimensionality. In our applications we fixed this to one to achieve comparability to WGCNA. However, our R package
is more flexible than WGCNA and allows for the optional export of the first i PCs with a fixed i or for each module
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the first j PCs which cumulatively explain at least xy% of variance. Principal component based dimension reduction
works particularly well if variables have linear relationships. If variables in modules would have non-linear relation-
ships other more flexible dimension reduction techniques such as autoencoders [37, 38] might be more suited for
calculation of aggregate measures. As the proposed module detection is ultimately based on the Pearson correlation
coefficient which measures the strength of the linear relationship PCA based aggregation of modules is well defined
as is observed by the high proportion of variance explained. If non-linear relationships between the features are of
interest a complementary method would be required.
In Netboost feature-wise distances are defined based on Pearson correlation coefficients, e.g. [34] constructs networks
based on partial correlations. In the form of Gaussian graphical models (GGM) partial correlations are frequently
applied for network construction [39, 40]. In [41] GGMs are combined with a filtering step to exclude insignificant
edges from the network much like Netboost. Partial correlations adjust for other variables in the network and identify
the independent connections between features. In contrast, in Netboost we integrate indirect connections even further
by the TOM. This is done to identify interacting subgroups irrespective of whether this interaction is direct or indirect.
The focus lies on modules rather than on the individual edges, and the incorporation of indirect connections further
stabilizes module detection.
As with GGMs a prime area of application beyond gene expression and DNA methylation is metabolome and proteome
data. Due to their inherent co-regulation structures they offer themself to a network based analysis as was recently
successfully demonstrated by combination of WGCNA on proteome data and a subsequent genome wide association
study in [42].
Datatype specific features, like dependency of CpG sites in close proximity, are not incorporated as a-priori information
in Netboost. While this could inform the network, we prefer a universal design for omics data in general. Therefore,
a known biological nexus can be used for module evaluation as was done in Section TCGA AML: Methylation and
gene expression predictive of overall survival.
In [43] the authors introduce Net-Cox which also introduces network theory to improve survival prediction in a high-
dimensional context. In contrast to our combination of Netboost and Coxboost, they introduce the estimated gene
co-expression structure directly to the penalty term of the Cox model. Net-Cox is thereby inherently designed for
survival analysis, whereas Netboost is more flexible in its application.
In the section Huntington’s disease: Gene expression and CAG repeats WGCNA might be improved by the tuning of
parameters as we only applied the standard settings and the achieved clustering superimposes the disease classifying
signals. Netboost kept a more compartmentalized and detailed network with the standard setting due to the applied
filtering step.
In the shown applications we prefer specificity over sensitivity with respect to the clusterings. While it might be okay
to miss an additional feature being part of a module we want to be sure about the selected features. Consistent with
this, we deem the Jaccard Index as more important to our applications as most features are unrelated. As shown in
Figure 6 Netboost is more robust than any of the competing clustering algorithms, when compared to WGCNA by the
adjusted Rand Index and the Jaccard Index. To an extent it trades some sensitivity for specificity as expected by the
concept of integrating a filter on the network edges. With the adjusted Rand Index and Jaccard Index we chose basic
measures of stability, which are especially reliable as they are used in a comparative fashion in identical resampling
setting with different methodologies. When trying to assess stability of multi-level clustering structures [44] or specific
modules [45] other measures might be more suitable.
The applied clustering technique on the dendrogram in WGCNA and Netboost was introduced and compared to other
methods in [20]. We kept the same cutting method to improve comparability. Primary applications of WGCNA are
related to identification of the network structure itself. With respect to this we regard Netboost as a complementary
approach designed to improve analysis including feature selection.
Netboost introduces the number of boosting steps as a parameter. This number can be chosen high as overfitting in
filter estimation would only result in a less stringent filter rather than bias. Possible extensions include a probing
based stopping criterion in the boosting step. Boosting could be stopped by inserting uninformative features without
the need to perform cross validation or a fixed number of boosting steps during generation of the filter. This would
automate the choice of boosting steps, while circumventing the often extensive additional computational load of cross-
validation. Another direction to extend Netboost is inclusion of unclustered features which are currently ignored in
primary analysis. This implies that isolated singular features can not achieve a significant impact on the outcome.
This is not true for all settings. In the primary analysis Xmodules could be combined with a filtering method on the
unclustered features.
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Conclusion
With Netboost we present an efficient dimension reduction technique based on boosting and weighted gene co-
expression networks distributed as a Bioconductor R package. By introducing the boosting-based filter combined
with the TOM and sparse hierarchical clustering combined with the dynamic tree cut procedure we were able to
extend efficiency and predictive performance simultaneously.
In the gene expression and DNA methylation examples this resulted in a 559- (TCGA AML) and 264-fold (HD) re-
duction of features for the primary analyses. Choosing eigengenes as summary measures we maximized the explained
variance within each modules without an assumptions-based extension to keep Netboost applicable to a diverse set of
biological experiments and primary analysis strategies. Here, we displayed applications to in vivo DNA methylation
array, RNA array and RNA-seq measurements from patient and mouse samples. Paired with the clustering reflecting
biological structures this leads to improvements in highdimensional survival analysis as well as in highdimensional
classification.
In the Section TCGA AML: Methylation and gene expression predictive of overall survival the molecular prediction
was improved by identification of a surrogate for clinical information within the molecular data and by the identifi-
cation of hematopoietic genes and genes encoding chromatin-modifying enzymes. In this application we were able
to first abstract new features from the highdimensional data (modules), demonstrate a higher robustness than state-of-
the-art alternative methods (cross-validation prediction errors) and validate the discovered correlates in an independent
dataset (phase II AMLSG 12-09 study). Numerous of these genes have been suspected to play a role in AML patho-
genesis before [46, 7]. Overall, the identified signature is promising for future research regarding AML pathogenesis
and as a prognostic/predictive marker. Furthermore, the association with chromatin-modifying enzymes could be
replicated in an independent DNA methylation data set from the phase II AMLSG 12-09 clinical trial [28] despite no
available gene expression measurements. In the AMLSG 12-09 study, the effect of substituting cytarabine by the DNA
methyltransferase inhibitor 5-azacitidine in AML induction therapy was studied. This trial tested the hypothesis that
5-azacytidine might reduce failure rates of intensive induction therapy particularly in AML patients with unfavorable
genetic features. It is of interest that validation of the chromatin associated module was successful in this independent
AML patient DNA methylation data set although the distribution of genetic aberrations in patients treated within the
AMLSG 12-09 trial differed considerably from AML patients of the TCGA data set. Particularly, patients with core-
binding factor AML, AML with mutated NPM1, and AML with FLT3 internal tandem duplication were excluded in
this trial.
In the section Huntington’s disease: Gene expression and CAG repeats Netboost outperformed the two other ap-
proaches and achieved the lowest prediction error. In direct comparison to WGCNA, Netboost kept more compart-
mentalized networks with eigengenes better reflecting their respective module and these eigengenes exhibiting stronger
associations with variables of interest. Additionally, separation between, network detection and association with the
trait of interest, allows for unbiased analysis and interpretation of the obtained structural information. Due to this,
our biological understanding of these complex diseases and experiments might benefit from the increase in prediction
accuracy and added information via the extracted network.
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Figure 2: .632+ prediction error estimates for AML survival models.
Figure 3: Dendrogram of the TCGA AML data. Dendrogram of the DNA methylation and gene expression features
in the TCGA AML data. The two rows below show the separation into modules by blockwise Weighted Gene Co-
expression Network Analysis (WGCNA) and Netboost.
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Figure 4: Variability of the .632+ prediction error estimates in AML survival models. Integrated prediction error
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XNetboost. The Kaplan-Meier benchmark value is indicated by a horizontal line. Red lines indicate the integrated .632+
prediction error estimates with the line for the Clinical + Netboost model (lowest error) being extended by a dashed
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Figure 5: Mis-classification rate for logistic regression models of the clinical score in AML. We compare randomly
selected features of the raw data with randomly selected modules and the modules selected for survival prediction
performance. The complexity of models is fixed to two and six to match the final survival models for Netboost and
WGCNA respectively. The horizontal line indicates the expected mis-classification rate at random. Asterisks indicate
significance of unpaired two-samples Student’s t-test (*** p <0.001, ** p <0.01, * p <0.05, NS. p ≥0.05). Only
neighbouring columns were tested.
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Figure 7: Chromatin modifying module eigengene distribution and Kaplan Meier in discovery and replication
data. A) shows the bimodal eigengene distribution of the TCGA AML DNA methylation and gene expression module
associated with chromatin modifying enzymes. The vertical line indicates at which point patients were stratified.
B) depicts the Kaplan Meier curves stratified by the modules eigengene for TCGA patients. C) shows the bimodal
eigengene distribution of the transferred module in AMLSG 12-09 DNA methylation data. The vertical line indicates
at which point patients were stratified. D) depicts the Kaplan Meier curves stratified by the modules eigengene for
AMLSG 12-09 patients.
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Figure 8: Variability of the .632+ prediction error estimates in TCGA Kidney Renal Clear Cell Carcinoma
(KIRC), Breast Invasive Carcinoma (BRCA) and Ovarian Serous Cystadenocarcinoma (OV) survival models.
Integrated prediction error curve estimates from single subsamples for CoxBoost on the full dataset, CoxBoost on
XWGCNA and CoxBoost on XNetboost. The Kaplan-Meier benchmark value is indicated by a horizontal line. Red lines
show the integrated .632+ prediction error estimates. Asterisks indicate significance of unpaired two-samples Student’s
t-test (*** p <0.001, ** p <0.01, * p <0.05, NS. p ≥0.05).
Figure 9: Dendrogram of Huntington’s disease data. Dendrogram of the gene expression features in the Hunt-
ington’s disease data. A) shows the separation into modules by blockwise Weighted Gene Co-expression Network
Analysis (WGCNA) and B), C) and D) show Netboost modules with 25, 20 and 15 boosting steps respectively.
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